Free tool
FAERS Monitor: Avonex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103628 or its brand name (Avonex, Interferon Beta-1a). Reports on generic versions are filed under their own applications.
Reports
146,156
Serious
66,610
46% of reports
Hospitalization
44,726
Death reported
7,095
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- multiple sclerosis relapse11,981
- influenza like illness10,427
- fatigue8,660
- fall8,142
- multiple sclerosis7,730
- gait disturbance7,252
- memory impairment7,181
- headache6,037
- pain5,895
- asthenia4,774
- malaise4,079
- drug ineffective4,051
- hypoaesthesia3,969
- injection site pain3,943
- pain in extremity3,912
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,740 |
| 2005 | 4,860 |
| 2006 | 3,370 |
| 2007 | 3,169 |
| 2008 | 4,352 |
| 2009 | 4,536 |
| 2010 | 13,680 |
| 2011 | 12,126 |
| 2012 | 14,126 |
| 2013 | 20,049 |
| 2014 | 14,664 |
| 2015 | 8,509 |
| 2016 | 8,747 |
| 2017 | 6,619 |
| 2018 | 5,772 |
| 2019 | 4,547 |
| 2020 | 3,934 |
| 2021 | 2,690 |
| 2022 | 2,369 |
| 2023 | 2,070 |
| 2024 | 1,427 |
| 2025 | 1,156 |
| 2026 | 619 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,908,003 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple sclerosis relapseSignal | 11,981 | 30.3 | 29.7 | 280,749 |
| multiple sclerosisSignal | 7,730 | 27.6 | 26.9 | 166,213 |
| influenza like illnessSignal | 10,427 | 20.7 | 20.3 | 171,664 |
| memory impairmentSignal | 7,181 | 7.9 | 7.7 | 41,153 |
| gait disturbanceSignal | 7,252 | 5.6 | 5.5 | 26,791 |
| hypoaesthesiaSignal | 3,969 | 3.9 | 3.8 | 8,362 |
| fallSignal | 8,142 | 3.6 | 3.5 | 15,031 |
| pain in extremity | 3,912 | 1.9 | 1.9 | 1,733 |
| injection site pain | 3,943 | 1.9 | 1.8 | 1,572 |
| asthenia | 4,774 | 1.8 | 1.8 | 1,832 |
| fatigue | 8,660 | 1.6 | 1.6 | 2,041 |
| headache | 6,037 | 1.4 | 1.4 | 672 |
| pain | 5,895 | 1.4 | 1.4 | 642 |
| malaise | 4,079 | 1.3 | 1.3 | 359 |
| drug ineffective | 4,051 | 0.4 | 0.4 | 3,059 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.